MediGene presents positive safety data from NV1020 trial

By Elaine Rigoli

Tampa, Fla., May 31 -MediGene AG published positive safety data obtained in a clinical trial of the cancer-killing virus NV1020 for the treatment of liver metastases.

The virus doses were well tolerated by all patients participating in the trial, and were easily combined with the subsequent standard tumor therapies.

There was no indication of a systemic herpes simplex virus infection or any clinically relevant side effects after administration of NV1020, according to a news release.

"We have achieved an important intermediate result of this trial. Safety requirements are extraordinarily stringent for a highly innovative technology such as our oncolytic viruses. We are glad that we have taken these hurdle in the first escalating stages, and eagerly await further results of the trial, especially regarding the average survival rate," chief executive officer Peter Heinrich said in the release.

NV1020 are herpes simplex viruses genetically modified for the specific destruction of tumor cells without harming healthy tissue.

The trial is designed for a repeated treatment of various groups of patients with different dosages of NV1020, followed by chemotherapy.

MediGene AG is a biotechnology company located in Martinsried, Germany.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.